Home » Stocks » CTSO

CytoSorbents Corporation (CTSO)

Stock Price: $9.34 USD 0.13 (1.41%)
Updated Jan 21, 2021 4:00 PM EST - Market closed
Market Cap 402.40M
Revenue (ttm) 36.48M
Net Income (ttm) -11.11M
Shares Out 41.59M
EPS (ttm) -0.31
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 21
Last Price $9.34
Previous Close $9.21
Change ($) 0.13
Change (%) 1.41%
Day's Open 9.21
Day's Range 9.12 - 9.40
Day's Volume 215,678
52-Week Range 4.00 - 11.55

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
PRNewsWire - 11 hours ago

MONMOUTH JUNCTION, N.J., Jan. 21, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology...

PRNewsWire - 2 days ago

MONMOUTH JUNCTION, N.J., Jan. 19, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology...

PRNewsWire - 1 week ago

MONMOUTH JUNCTION, N.J., Jan. 11, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology...

PRNewsWire - 2 weeks ago

MONMOUTH JUNCTION, N.J., Jan. 4, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology ...

PRNewsWire - 1 month ago

MONMOUTH JUNCTION, N.J., Dec. 17, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology...

PRNewsWire - 1 month ago

MONMOUTH JUNCTION, N.J., Dec. 9, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology ...

PRNewsWire - 1 month ago

MONMOUTH JUNCTION, N.J., Dec. 2, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader that is commercializing its CytoSorb® blood purification tec...

PRNewsWire - 1 month ago

MONMOUTH JUNCTION, N.J., Nov. 25, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology...

PRNewsWire - 1 month ago

MONMOUTH JUNCTION, N.J., Nov. 23, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology...

PRNewsWire - 2 months ago

MONMOUTH JUNCTION, N.J., Nov. 12, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology...

Seeking Alpha - 2 months ago

Cytosorbents Corporation (CTSO) CEO Phillip Chan on Q3 2020 Results - Earnings Call Transcript

PRNewsWire - 2 months ago

MONMOUTH JUNCTION, N.J., Nov. 4, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat d...

PRNewsWire - 3 months ago

MONMOUTH JUNCTION, N.J., Oct. 21, 2020 /PRNewswire/ -- CytoSorbents Corporation (CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to trea...

PRNewsWire - 3 months ago

MONMOUTH JUNCTION, N.J., Oct. 9, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader specializing in blood purification, announced today that the...

PRNewsWire - 4 months ago

MONMOUTH JUNCTION, N.J., Sept. 21, 2020 /PRNewswire/ -- CytoSorbents Corporation (Nasdaq: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technolog...

PRNewsWire - 4 months ago

MONMOUTH JUNCTION, N.J., Sept. 8, 2020 /PRNewswire/ -- CytoSorbents Corporation (Nasdaq: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology...

PRNewsWire - 5 months ago

MONMOUTH JUNCTION, N.J., Aug. 17, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO) has entered into separate agreements with InvoSurg Inc.

Seeking Alpha - 5 months ago

Cytosorbents Corporation (CTSO) CEO Phillip Chan on Q2 2020 Results - Earnings Call Transcript

Benzinga - 5 months ago

Shares of CytoSorbents (NASDAQ:CTSO) fell 2.15% in after-market trading after the company reported Q2 results.

PRNewsWire - 5 months ago

MONMOUTH JUNCTION, N.J., Aug. 4, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat d...

Benzinga - 5 months ago

CytoSorbents (NASDAQ: CTSO) releases its next round of earnings this Tuesday, August 04.

PRNewsWire - 5 months ago

MONMOUTH JUNCTION, N.J., Aug. 3, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat d...

PRNewsWire - 5 months ago

MONMOUTH JUNCTION, N.J., July 31, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader specializing in blood purification, announced today that th...

PRNewsWire - 5 months ago

MONMOUTH JUNCTION, N.J., July 28, 2020 /PRNewswire/ -- CytoSorbents Corporation (Nasdaq: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology...

PRNewsWire - 5 months ago

MONMOUTH JUNCTION, N.J., July 28, 2020 /PRNewswire/ -- CytoSorbents Corporation (CTSO), CytoSorbents Corporation (CTSO), a critical care immunotherapy leader commercializing its CytoSorb® bloo...

The Motley Fool - 5 months ago

The company has priced its recently announced stock offering.

PRNewsWire - 5 months ago

MONMOUTH JUNCTION, N.J., July 22, 2020 /PRNewswire/ -- CytoSorbents Corporation (Nasdaq: CTSO) (the "Company"), a critical care immunotherapy leader commercializing its CytoSorb® blood purific...

The Motley Fool - 6 months ago

A stock offering overshadowed the company's impressive preliminary second-quarter results.

24/7 Wall Street - 6 months ago

The S&P 500 closing up 0.8% at 2,251.84 and with the NASDAQ closing up 2.5% at 10,767.09, many investors are wondering how stocks keep rising despite the major recession in the time of a COVID...

Other stocks mentioned: ACAD, GNW, HIBB, IBM, LLNW, NBEV, QIWI, TNXP
PRNewsWire - 6 months ago

MONMOUTH JUNCTION, N.J., July 20, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat d...

PRNewsWire - 6 months ago

MONMOUTH JUNCTION, N.J., July 20, 2020 /PRNewswire/ -- CytoSorbents Corporation (Nasdaq: CTSO) (the "Company") a critical care immunotherapy leader commercializing its CytoSorb® blood purifica...

PRNewsWire - 6 months ago

MONMOUTH JUNCTION, N.J., June 29, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat d...

PRNewsWire - 6 months ago

MONMOUTH JUNCTION, N.J., June 24, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat d...

PRNewsWire - 7 months ago

MONMOUTH JUNCTION, N.J., June 9, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a critical care immunotherapy leader specializing in blood purification, announced today that it w...

Seeking Alpha - 7 months ago

Below is a list of six companies with promising Covid-19 treatments in various stages of development, and the reasons why I have invested in them.

Other stocks mentioned: ATHX, CMRX, CYDY, MESO
PRNewsWire - 7 months ago

MONMOUTH JUNCTION, N.J., May 27, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology ...

Seeking Alpha - 8 months ago

Cytosorbents Corporation (CTSO) CEO Phillip Chan on Q1 2020 Results - Earnings Call Transcript

Seeking Alpha - 8 months ago

Cytosorbents: COVID-19 Has Presented A Bullish Opportunity

Market Watch - 9 months ago

Shares of CytoSorbents Corp. CTSO, +28.52% gained 28.7% in trading on Monday following a Food and Drug Administration announcement late on Friday that grants an emergency use authorization to ...

Seeking Alpha - 10 months ago

CytoSorbents Corporation (CTSO) CEO Phillip Chan on Q4 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Cytosorbents Corporation (CTSO) CEO Phillip Chan on Q3 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Cytosorbents Corporation (CTSO) CEO Phillip Chan on Q2 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Cytosorbents Corporation (CTSO) CEO Phillip Chan on Q1 2019 Results - Earnings Call Transcript

About CTSO

Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. The company's flagship product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary ... [Read more...]

Industry
Medical Devices
Founded
1997
CEO
Phillip Chan
Employees
153
Stock Exchange
NASDAQ
Ticker Symbol
CTSO
Full Company Profile

Financial Performance

In 2019, CytoSorbents's revenue was $24.95 million, an increase of 10.87% compared to the previous year's $22.50 million. Losses were -$19.27 million, 11.9% more than in 2018.

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for CytoSorbents stock is "Strong Buy." The 12-month stock price forecast is 14.88, which is an increase of 59.31% from the latest price.

Price Target
$14.88
(59.31% upside)
Analyst Consensus: Strong Buy